Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Onconetix, Inc. - Common Stock
(NQ:
ONCO
)
0.4764
-0.0716 (-13.07%)
Delayed Quote
Updated: 2:50 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Onconetix, Inc. - Common Stock
< Previous
1
2
Next >
CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
September 14, 2026
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
September 14, 2026
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events
September 03, 2026
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series
August 06, 2026
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG
August 05, 2026
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation
July 07, 2026
From
Onconetix, Inc.
Via
GlobeNewswire
NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Development of PNKP Inhibitors in Oncology Drug Development
June 26, 2026
From
NetworkNewsWire
Via
GlobeNewswire
Onconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District
June 24, 2026
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix, Inc. Announces 1-for-10 Reverse Stock Split
May 19, 2026
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
May 13, 2026
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson
April 09, 2026
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update
April 02, 2026
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors
March 31, 2026
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix Highlights Realbotix’s Role in Ericsson’s World-First 6G Trial Demonstration
March 25, 2026
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix, Inc. Announces 1-for-5 Reverse Stock Split
March 23, 2026
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company
February 12, 2026
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
September 26, 2025
From
Onconetix, Inc.
Via
GlobeNewswire
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
September 26, 2025
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM
September 22, 2025
From
Onconetix, Inc.
Via
GlobeNewswire
ONCO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Onconetix, Inc. Is Fair to Shareholders
July 16, 2025
From
Halper Sadeh LLC
Via
Business Wire
Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement
July 16, 2025
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel
June 16, 2025
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders
June 11, 2025
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
May 22, 2025
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
April 30, 2025
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.
April 08, 2025
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort
March 24, 2025
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress
March 19, 2025
From
Onconetix, Inc.
Via
GlobeNewswire
Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing
December 12, 2024
From
Onconetix, Inc.
Via
GlobeNewswire
Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit
October 03, 2024
From
Onconetix, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
